» Articles » PMID: 28450742

Aptamers As Targeted Therapeutics: Current Potential and Challenges

Overview
Specialty Pharmacology
Date 2017 Apr 29
PMID 28450742
Citations 65
Authors
Affiliations
Soon will be listed here.
Citing Articles

Aptamer based immunotherapy: a potential solid tumor therapeutic.

Mathavan S, Tam Y, Mustaffa K, Tye G Front Immunol. 2025; 16:1536569.

PMID: 40034705 PMC: 11873091. DOI: 10.3389/fimmu.2025.1536569.


Engineered extracellular vesicles with sequential cell recruitment and osteogenic functions to effectively promote senescent bone repair.

Qi L, Wang J, Yan J, Jiang W, Ge W, Fang X J Nanobiotechnology. 2025; 23(1):107.

PMID: 39939879 PMC: 11823168. DOI: 10.1186/s12951-025-03168-6.


Oligomeric amyloid-β targeted contrast agent for MRI evaluation of Alzheimer's disease mouse models.

Park J, Tian Y, Kim S, Park C, Kim Y, Chung H Front Pharmacol. 2024; 15:1392729.

PMID: 38895620 PMC: 11184063. DOI: 10.3389/fphar.2024.1392729.


Assembling the RNA therapeutics toolbox.

Teng M, Xia Z, Lo N, Daud K, He H Med Rev (2021). 2024; 4(2):110-128.

PMID: 38680684 PMC: 11046573. DOI: 10.1515/mr-2023-0062.


Robust Fluorometric Aptamer Assay for Direct and Rapid Detection of Clinical Isolates of spec.

Zhang Y, Xing H, Bolotnikov G, Kramer M, Bozdogan A, Kissmann A Int J Mol Sci. 2024; 25(6).

PMID: 38542416 PMC: 10970908. DOI: 10.3390/ijms25063444.


References
1.
Zhou J, Rossi J . Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2016; 16(3):181-202. PMC: 5700751. DOI: 10.1038/nrd.2016.199. View